Terrill K. McClanahan

Merck & Co., Inc., Rahway, NJ, USA (United States)

Publishes on Cancer Immunotherapy and Biomarkers, Psoriasis: Treatment and Pathogenesis, Immunotherapy and Immune Responses. 150 papers and 38.9k citations.

PubIndex Score21Top 79% · mid-careerHow it's scored

150Publications

38.9kTotal Citations

First publication: 1984First senior author: 2017

Cancer Immunotherapy and Biomarkers Psoriasis: Treatment and Pathogenesis Immunotherapy and Immune Responses Immune Cell Function and Interaction T-cell and B-cell Immunology

Top publicationsby citations

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Terrill K. McClanahan, Jonathan D. Cheng et al.|Journal of Clinical Investigation|2017

Cited by 3.9k

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Răzvan Cristescu, David R. Kaufman, Robin Mogg et al.|Science|2018

Cited by 2.3k

CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic Cells

David R. Greaves, Thomas J. Schall, Wei Wang et al.|The Journal of Experimental Medicine|1997

Cited by 360

The Myeloid Receptor PILRβ Mediates the Balance of Inflammatory Responses through Regulation of IL-27 Production

Cristina M. Tato, Barbara Joyce-Shaikh, Yi Chen et al.|PLoS ONE|2012

Cited by 23